Exclusive-Medicaid fuels US coverage of Novo, Lilly weight-loss drugs
State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access to Novo Nordisk's Wegovy or Eli Lilly's Zepbound, according to the AXIACI ...
Medicaid fuels US coverage of Novo, Lilly weight-loss drugs
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...
NBC Los Angeles on MSN8h
FDA weighs in on diet drug shortage, creating more confusion about compounding
As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.
People without diabetes can use continuous glucose monitors. But should they?
CGMs are prescribed to diabetics to monitor their blood sugar. They're now available and becoming wildly popular for over-the ...
Hosted on MSN11h
Over 50% of U.S. Adults Qualify for Ozempic, Wegovy
All met the criteria for at least one of three indications that the drug is currently approved for -- diabetes, weight ...